Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs

被引:16
作者
Ashton, JA [1 ]
Farese, JP [1 ]
Milner, RJ [1 ]
Lee-Ambrose, LM [1 ]
van Gilder, JM [1 ]
机构
[1] Univ Florida, Coll Vet Med, Dept Small Anim Clin Sci, Gainesville, FL 32610 USA
关键词
D O I
10.2460/ajvr.2005.66.885
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Objective-To determine the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells and non-neoplastic cells from dogs. Sample Population-3 osteosarcoma and 1 fibroblast cell lines derived from dogs. Procedure-Cell counts and cell viability assays were performed in cultures of osteosarcoma cells (POS, HMPOS, and COS31 cell lines) and fibroblasts after 24, 48, and 72 hours of incubation with pamidronate at concentrations of 0.001 to 1,000 mu M or with no drug (control treatment). Percentage viability was determined in cell samples for each concentration of pamidronate and each incubation time. A DNA fragmentation analysis was performed to assess bisphosphonate-induced apoptosis. Results-Osteosarcoma cell viability decreased significantly in a concentration- and time-dependent manner at pamidronate concentrations ranging from 100 to 1,000 mu M, most consistently after 48 and 72 hours' exposure. In treated osteosarcoma cells, the lowest percentage cell viability was 34% (detected after 72 hours' exposure to 1,000 mu M pamidronate). Conversely, 72 hours' exposure to 1,000 mu M pamidronate did not significantly reduce fibroblast viability (the lowest percentage viability was 76%). After 72 hours of exposure, pamidronate did not cause DNA fragmentation in POS or HMPOS cells. Conclusions and Clinical Relevance-Results indicate that pamidronate may have the potential to inhibit osteosarcoma growth in dogs, possibly through a nonapoptotic mechanism. The clinical relevance of these in vitro findings remains to be determined, but administration of pamidronate may potentially be indicated as an adjuvant treatment in chemotherapeutic protocols used in dogs.
引用
收藏
页码:885 / 891
页数:7
相关论文
共 43 条
[21]   PHARMACOKINETICS OF PAMIDRONATE IN PATIENTS WITH BONE METASTASES [J].
LEYVRAZ, S ;
HESS, U ;
FLESCH, G ;
BAUER, J ;
HAUFFE, S ;
FORD, JM ;
BURCKHARDT, P .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (10) :788-792
[22]   Bisphosphonates: A review of their pharmacokinetic properties [J].
Lin, JH .
BONE, 1996, 18 (02) :75-85
[23]   Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras [J].
Luckman, SP ;
Hughes, DE ;
Coxon, FP ;
Russell, RGG ;
Rogers, MJ .
JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (04) :581-589
[24]   Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line [J].
Mackle, PS ;
Fisher, JS ;
Zhou, H ;
Choong, PFM .
BRITISH JOURNAL OF CANCER, 2001, 84 (07) :951-958
[25]   Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro [J].
Mathov, I ;
Plotkin, LI ;
Sgarlata, CL ;
Leoni, J ;
Bellido, T .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (11) :2050-2056
[26]   Bone allografts and adjuvant cisplatin for the treatment of canine appendicular osteosarcoma in 18 dogs [J].
Morello, E ;
Buracco, P ;
Martano, M ;
Peirone, B ;
Capurro, C ;
Valazza, A ;
Cotto, D ;
Ferracini, R ;
Sora, M .
JOURNAL OF SMALL ANIMAL PRACTICE, 2001, 42 (02) :61-66
[27]  
OBRIEN MG, 1993, COMP CONT EDUC PRACT, V15, P939
[28]   PAMIDRONATE TREATMENT IN PATIENTS WITH TUMOR-ASSOCIATED HYPERCALCEMIA - PHARMACOLOGICAL EFFECTS AND PHARMACOKINETICS [J].
OISO, Y ;
TOMITA, A ;
HASEGAWA, H ;
ARIYOSHI, Y ;
NIINOMI, M ;
YAMAMOTO, M ;
TAKANO, T ;
SAKIYAMA, N .
ENDOCRINE JOURNAL, 1994, 41 (06) :655-661
[29]  
Poirier V J, 2003, Vet Comp Oncol, V1, P207, DOI 10.1111/j.1476-5810.2003.00026.x
[30]   Pharmacokinetics of alendronate [J].
Porras, AG ;
Holland, SD ;
Gertz, BJ .
CLINICAL PHARMACOKINETICS, 1999, 36 (05) :315-328